Latest news with #HiFi
Forbes
20-05-2025
- Forbes
Marantz Unveils Two New Reference-Quality Home Theater Components
Premium AV and Hi-Fi audio brand Marantz has today taken the wraps off a pair of new additions to its 'reference-quality' component range in the shape of the AV 20 AV pre-amp and AMP 20 power amplifier. Designed to join and complement the award-winning AV 10 pre-amp, AMP 10 power amp and CINEMA 30 AVR product family, the AV 20 and AMP 20 expand the variety of system configurations Marantz's high-end product range can support. Both new units are manufactured at the brand's premium factory, the Shirakawa Audio Works in Japan, and have been meticulously honed and refined by a Marantz Sound Master (a select group of experts within Marantz who are considered to have a particularly high level of listening expertise and judgment they can apply to tuning premium products). The AV 20 Pre-Amp and AMP 20 power amp. Photo: Marantz The AV 20 and AMP 20 both sport the latest iteration of Marantz's iconic 'porthole display' design, together with selectable side illumination, applied to an uncompromising build quality based on a multi-layer, copper-heavy chassis. The new devices' remote controls are made from aluminium, too, as well as offering button backlighting to make them easy to use in dark rooms. Let's get next into the specifics of each model. The AV 20 carries the latest and most powerful Analog Devices SHARC Dual-core DSP chipset, partnered with uncompromising 32-bit two-channel DACs with dedicated jitter reduction. This ensures that the AV 20 can precisely decode and process every possible form of incoming audio technology, including the most high-resolution stereo formats and every current form of immersive audio, including Dolby Atmos, IMAX Enhanced, DTS:X Pro and AURO-3D. The AV 20's premium processing system has been combined with the Audyssey MultEQ XT32 advanced room optimization system, which automatically calibrates sound to take into account your sound system's speaker sizes, speaker distances, level adjustment and many more factors besides. All with a focus, of course, on making sure the AV 20 is able to adapt its audio mastery to as wide a range of speakers and listening environments as possible. Detail of the Marantz AV 20 Pre-Amp. Photo: Marantz Marantz has also equipped the AV 20 with Dirac Live Room Correction plus the Dirac Live Bass Control, enabling you to integrate up to four separated and fully optimized subwoofers into your sound system. Plus, for the first time in a Marantz product, the AV 20 will eventually (following an upcoming firmware update) carry the Dirac Live Active Room Treatment (ARC) technology that's claimed to create an unprecedentedly cohesive and tonally consistent listening experience. The AV 20 carries seven HDMI inputs all capable of supporting video feeds up to 8K/60Hz or 4K/120Hz, as well as multiple analog and digital inputs and an expansive range of custom installation-optimized features that enable it to adapt to pretty much any scale of set up, from relatively small media rooms to large home theater installations. The AV 20's discrete HDAM SA-3 preamplifier stage feeds up to 13.4 channels using either RCA or XLR outputs and, finally, the AV 20 supports the latest HEOS multi-room platform, making it as easy as possible to access content streamed through Roon, Spotify Connect, TIDAL Connect, Qobuz Connect, AirPlay 2 and Bluetooth. Finally, the AV 20 uses a fold-down front panel on its fascia to hide its relatively less-used controls, to retain that distinctive premium Marantz porthole look. Summary of key features: * SHARC dual-core DSP with 32-bit two-channel DACs * Timeless design with the iconic Marantz porthole display and modern high-definition on-screen display * 8K support for x7 HDMI inputs with x3 HDMI outputs * Support for Dolby Atmos™, IMAX Enhanced™, DTS:X Pro™ and AURO 3D™ * Audyssey MultEQ XT32 advanced room optimization included, plus Dirac Live calibration, including Bass Control and Active Room Treatment options, available at extra cost * Access to streaming services via HEOS®, Spotify Connect, TIDAL Connect, Qobuz Connect, Roon Ready, AirPlay 2, Bluetooth and more, all built-in * 12 x 200W Power Amplifier, with bi-amping and 400W BTL mode available Detail of the Marantz AMP 20. Photo: Marantz The AMP 20 is configured to deliver up to 12 channels of power with 200W per channel (8ohms, 1kHz, THD 0.05% with two channels driven). It also allows users to reconfigure pairs of 200W amp channels into bridged-tied-load (BTL) outputs, delivering up to six channels of 400W if you're lucky enough to have a speaker system that might benefit from that. Or you can opt to bi-amp up to six speakers, with both XLR and RCA inputs available. Other examples of how the AMP 20 might be used are as a powerful amplifier upgrade for owners of Marantz's CINEMA 30 AVR, or as a complement to AV 10 preamplifiers, where fewer channels of power are required. (Similarly, AV 20 buyers could, say, opt to buy the 16-channel AMP 10 Power Amplifier instead of the AMP 20 if they require more than the 12 channels of power offered by the AMP 20.) The Marantz AV20 and AMP 20 are both available to buy from today from selected retailers, with each product available for $6,500 in the U.S., €5,500 in Europe and £4,750 in the U.K. —— Related reading Kaleidescape Launches New Entry-Level Movie Player Samsung Adds New 3D Sound Technology To 2025 TV And Soundbar Range Hisense Unveils New Home Theater Audio System Specifically Designed For King-Sized TVs
GSM Arena
14-05-2025
- Business
- GSM Arena
Nothing partners up with KEF for multiple audio products coming this year
Vlad 14 May 2025 Nothing Android Today, Nothing has announced a long-term strategic partnership with iconic British audio pioneer KEF "to usher the company's next chapter in sound". The collaboration brings together KEF's six decades of Hi-Fi audio expertise with Nothing's design-led approach to technology. Expect this to result in Nothing expanding into new audio categories, and several acoustically co-developed products are already in the works and launching later this year. Remember those Nothing headphones that were rumored in February? KEF might have something to do with them. At least we hope so. But the company mentions several products, so we're excited to see where this will lead - Nothing earbuds tuned by KEF? That's a very interesting prospect, headphones aside. The press release says that for Nothing, this partnership lets it diversify its audio offerings and enter new product categories, while for KEF, it "opens new pathways to share its expertise with a wider audience through a fresh design and technology lens". Andrew Freshwater, Head of Smart Products Marketing at Nothing, said: KEF is one of the most respected names in audio, and we're proud to partner with them as we take the next step in expanding Nothing's audio journey. By combining KEF's decades of expertise with our design-led approach to technology, we're laying the groundwork for a new standard in everyday listening. Our products launching later this year mark the beginning of an exciting new chapter of our collaboration and the future of Nothing Audio. Grace Lo, President & Head of Global Marketing at KEF, said: At KEF, we've always believed in the power of great sound to inspire and connect people. This partnership allows us to bring our acoustic heritage into a fresh context – working with a brand that shares our dedication to innovation, quality, and design. Together, we're setting out to redefine what premium audio can look and feel like for the next generation.
Yahoo
05-05-2025
- Health
- Yahoo
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand
Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio's HiFi sequencing technology at population scale - an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration highlights Thailand's growing leadership in precision medicine and offers a potential model for countries seeking to modernize newborn screening with genome-wide approaches. 'Our shared goal is to establish a robust and scalable research model for genomic newborn screening that helps uncover the genetic basis of undiagnosed conditions from birth,' said Professor Vorasuk Shotelersuk from the Center of Excellence for Medical Genomics, Chulalongkorn University, Thailand. 'We are excited to work with PacBio to bring this vision closer to reality for families in Thailand.' Traditional newborn screening programs have relied on targeted panels that detect a limited subset of conditions based on specific molecular pathologies. Recent advances in genome sequencing now make it possible to take a broader, more comprehensive approach, starting at birth. PacBio's HiFi WGS leverages long-read technology to generate highly accurate, complete genomic data, including regions that are typically inaccessible to short-read methods. In addition to resolving structural variants and repeat expansions, HiFi WGS captures epigenomic information in parallel, giving researchers a multidimensional view of the genome. This level of detail opens the door to identifying a wider range of genetic variants, many of which are implicated in early-onset and rare diseases that previously went undetected. 'Every child deserves the best possible start to life, and that begins with giving families and clinicians access to comprehensive genomic information from the very beginning,' said Christian Henry, President and Chief Executive Officer of PacBio. 'This collaboration demonstrates how advanced sequencing technologies like HiFi can enable broader insights at birth. It's deeply aligned with our mission at PacBio to make high-quality genomic information accessible where it's needed most, and we're proud to support Chulalongkorn University and Thailand as they lead the way in laying the foundation for a new model of care.' This collaboration positions Thailand as a regional leader in population-scale genomics and reflects Asia Pacific's expanding influence in the global genomics landscape. With an established foundation in public health and translational research, Thailand is uniquely prepared to explore how whole genome sequencing can enhance national healthcare strategies, beginning with newborn screening. By applying PacBio's HiFi long-read sequencing to this early-stage initiative, researchers gain a more comprehensive view of the genome, enabling the detection of variants that are often missed by traditional methods. The ability to capture a wider spectrum of genetic risk at birth sets a new benchmark for the potential of early disease detection, while also contributing to broader goals in carrier screening and public health planning. For Thailand, this project strengthens its role in advancing precision medicine and lays critical groundwork for future data-sharing frameworks and cross-border research collaborations that can inform more equitable and effective genomic healthcare worldwide. About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. About Faculty of Medicine, Chulalongkorn University in Thailand Chulalongkorn University is the oldest national university in the Kingdom of Thailand. The university has been active in international research activities and is committed to creating knowledge and innovation to transform Thai society into a creative and sustainable future. As part of the university's mission is to contribute the knowledge gained to the sustainable development of the country and society, the Faculty of Medicine is also actively involved in sharing knowledge with society through collaboration between industry, government, and Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, the benefits or expected benefits of using, PacBio products or technologies, including in connection with Thailand's efforts to integrate PacBio products into newborn screening; establishing a research model that may uncover the genetic basis of undiagnosed conditions, improve outcomes, ease uncertainty or offer answers earlier, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks inherent in developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption 'Risk Factors.' These forward-looking statements, including PacBio's preliminary unaudited financial information and PacBio's financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. Contacts (PacBio) Investors: Todd Friedmanir@ Media:pr@ Contacts (Chulalongkorn University) Media:prmdcu@ in to access your portfolio
Yahoo
19-02-2025
- Business
- Yahoo
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA. A live webcast of the event can be accessed at the company's investors page at A replay of the webcast will be available for at least 30 days following the event. About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Contacts Investors:Todd Friedmanir@ Media:pr@
Yahoo
17-02-2025
- Business
- Yahoo
Spotify's Music Pro could have this killer feature for creators
When you buy through links on our articles, Future and its syndication partners may earn a commission. It's now been almost four years to the day since Spotify promised to introduce a new HiFi tier offering lossless HD audio by the end of 2021. To date, nothing has materialized, other than lots of rumors about what else a high-end tier might contain to keep up with the likes of Apple Music, Amazon Music Unlimited and Tidal, which all already offer lossless audio. The most recent official acknowledgement came in a 2024 earnings call, when CEO Daniel Ek confirmed that Spotify Deluxe was in the works later in the year. True to form, it missed that deadline, but a new report from Bloomberg suggests something may finally arrive in 2025 — and it actually sounds quite exciting. Now called Music Pro — by our count the fourth name for it, after HiFi, Supremium and Deluxe — the most exciting reported feature is the ability for subscribers to 'mix together songs from different artists.' This will in part lean on artificial intelligence, according to Bloomberg's sources, which could lower the bar of technical skill needed for creativity to flourish. On top of this and the higher-quality audio, the company is also apparently 'testing various ways to sell concert tickets, such as giving fans access to presales or better seats.' This is at the 'preliminary talks' stage with promoters and ticket sellers. While the article suggests that the service could cost as much as $5.99 a month on top of an existing subscription (which currently ranges from $5 per month for students to $20 for families), neither pricing nor the launch timeline have been finalized, because Spotify is yet to acquire rights from all the major record labels, the sources claim. As you might expect, however, price will vary by geography, with lower costs in 'less-developed markets.' This isn't the first time we've heard about possible extras Spotify has considered to try and tempt subscribers to pay for an add-on. Indeed, last April, a Reddit user found the Music Pro name in a code dive, along with references to lossless audio, 'advanced mixing tools', the ability to filter your music library by mood or activity and headphone optimization. While some of these features aren't mentioned in today's report, it's possible they will be part of the software eventually. Bloomberg's sources claim that Spotify aims to add 'tools and features over time' and will 'test many options over the course of this year.' Hopefully that means that 2025 is the year the app finally catches up with the best music streaming services on the all-important audio quality metric — for serious audiophiles, anything else is just a bonus.
